This is the transcript of part 2 of my podcast interview with Christus Health SVP/CIO George Conklin. I suggest reading part 1 first.
David Williams: The 2004 to 2006 standardization initiative is very impressive. A lot of organizations probably thought that…
This is the transcript of part 1 of my podcast interview with Christus Health SVP/CIO George Conklin.
David Williams: This is David E. Williams, co-founder of MedPharma Partners and author of the Health Business Blog. I’m speaking today with George Conklin. …
In part 1 of our podcast interview, Christus Health SVP/CIO George Conklin described describes how his 44-hospital system leverages IT to support its business. In part 2, he explains how organizational culture, psychology, technology and leadership interacted to enable the…
In this podcast interview, Christus Health’s SVP/CIO George Conklin describes how his 44-hospital system leverages IT to support its business. The overall organization has a three-part strategy:
This is the transcript of my recent podcast interview with Medco’s Chief Medical Officer Dr. Robert Epstein and DNA Direct’s CEO, Ryan Phelan.
David Williams: This is David E. Williams, co-founder of MedPharma Partners and author of the Health Business Blog.…
Pharmaceutical Benefit Manager Medco Health recently acquired DNA Direct, which provides genetic testing and support services for genomic medicine. The acquisition represents a broadening of Medco’s focus from pharmacogenomics to a fuller range of genetic tests, and helps DNA Direct…
This is the transcript of my recent podcast interview with Quantros co-founder and CEO Dr. Sanjaya Kumar.
David Williams: This is David E. Williams, co-Founder of MedPharma Partners and author of the Health Business Blog. I’m speaking today with Dr. Sanjaya…
Quantros provides software and services to the health care industry, with a focus on safety, risk management, quality and performance improvement. I spoke recently with Dr. Sanjaya Kumar, CEO and founder about a number of current topics, including:
Pfizer, “the world’s premier biopharmaceutical R&D organization,” plans to cut research spending by up to $3B reports this Wall Street Journal story. This, says WSJ, is “an attempt to wring efficiencies following its take-over of Wyeth without sacrificing future product…
This is the transcript of Part 2 of my recent podcast interview with Dr. Robert Wachter and Dr. Arpana Vidyarthi of UCSF.
In Part 1, Vidyarthi and Wachter provided an overview of the traditional case review process and discuss their progress…
